FIELD: immunology.
SUBSTANCE: disclosed is a method of producing an antibody or fragment thereof.
EFFECT: present invention can find further application in production of such an antibody as Ranibizumab.
3 cl, 7 dwg, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| Fab FRAGMENT OF HUMANIZED ANTIBODY AGAINST VEGF AND ITS USE | 2020 |
|
RU2802960C2 |
| CHIMERIC ANTIBODY/T-CELL RECEPTOR STRUCTURES AND THEIR APPLICATIONS | 2016 |
|
RU2767209C2 |
| NEW ANTI-IL13 ANTIBODIES AND USE THEREOF | 2020 |
|
RU2752833C1 |
| ANTIBODIES AGAINST PROGRAMMED CELL DEATH LIGAND 1 AND THEIR USE | 2020 |
|
RU2786235C1 |
| DNA ANTIBODY CONSTRUCTIONS FOR USE AGAINST LYME DISEASE | 2017 |
|
RU2813829C2 |
| CELLS EXPRESSING CHIMERIC ACTIVATING RECEPTORS AND CHIMERIC STIMULATING RECEPTORS AND THEIR USE | 2018 |
|
RU2780020C2 |
| ANTIBODIES TARGETING EPN1 | 2019 |
|
RU2816856C2 |
| THIOREDOXIN-1 EPITOPE AND MONOCLONAL ANTIBODY SPECIFICALLY BINDING TO IT | 2018 |
|
RU2797266C2 |
| THIOREDOXIN-1 EPITOPE BINDING SPECIFICALLY TO MONOCLONAL ANTIBODY | 2018 |
|
RU2804126C2 |
| THIOREDOXIN-1 EPITOPE BINDING SPECIFICALLY TO MONOCLONAL ANTIBODY | 2018 |
|
RU2804772C2 |
